Open AccessEvaluation of the VersaTREK System Compared to the Bactec MGIT 960 System for First-Line Drug Susceptibility Testing of Mycobacterium tuberculosis
Author(s) -
Mateu Espasa,
M. Salvadó,
E. Vicente,
Griselda Tudó,
Fernando Alcaide,
Pere Coll,
N Martín-Casabona,
Montserrat Torra,
D. Fontanals,
Juan Vicente GonzálezMartín
Publication year - 2011
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.06432-11
Subject(s) - ethambutol , isoniazid , pyrazinamide , mycobacterium tuberculosis , streptomycin , tuberculosis , medicine , microbiology and biotechnology , antibiotics , biology , pathology
The aim of this study was to evaluate the reliability of the VersaTREK system for Mycobacterium tuberculosis drug susceptibility testing compared with results obtained with the Bactec MGIT 960 system. A total of 67 strains were evaluated. Overall agreement was at 98.5%. Kappa indexes were 1.0 for isoniazid, rifampin, and ethambutol, 0.937 for pyrazinamide, and 0.907 for streptomycin. The VersaTREK system is validated for M. tuberculosis drug susceptibility testing.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom